A Phase 1 interventional study of APG777 and APG990 in Atopic Dermatitis, sponsored by Apogee Therapeutics, Inc.. Active, not recruiting at 20 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Apogee Therapeutics, Inc. (part of AbbVie) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Dermatitis, Atopic by AbbVie — 3 open to participants now, 12 under way, 4 of them phase 3. Dermatitis, Atopic · AbbVie.
Among the 34 studies in Dermatitis, Atopic by AbbVie, this one is the 16th largest by enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 in phase 1, reaches primary completion later than 1 of the 11 other live ones, and was the 33rd registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →3 of the 34 studies in Dermatitis, Atopic by AbbVie are open now, in 9 countries. Recruiting first, the newest first:
Apogee Therapeutics, Inc. · Sites in United States, Canada, Czechia and 6 more countries
Ages 18+
AbbVie · Sites in United States
Ages 18–75
AbbVie
Ages 18–64
By country, each count listing its studies:
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is close to the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 228 across the 22 interventional studies, 300 across the 11 observational. Of the 19 that completed or were terminated, 8 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Apogee Therapeutics, Inc., one of the names counted as AbbVie. Under that name alone:
Apogee Therapeutics, Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
7 of the studies in Dermatitis, Atopic by AbbVie that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT06701331Phase 3AbbVieSafety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis | 2027-01 |
| NCT06395948Apogee Therapeutics, Inc.A Study Evaluating APG777 in Atopic Dermatitis | 2026-11 |
| NCT05669794AbbVieAn Observational Study to Assess Change in Disease Activity and Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in Real World | 2027-02 |
| NCT06524635AbbVieA Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab | 2027-02 |
Add all 7 to your calendar (.ics) → With an account.
Among the 34 studies in Dermatitis, Atopic by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic (PK) parameters of the combination of APG777 + APG990 in adults with moderate-to-severe atopic dermatitis (AD), in comparison to dupilumab. The duration of the study will be approximately 82 weeks for each participant and will consist of a Screening Period (up to 6 weeks), Treatment Period (Baseline-Week 24), and Follow-up Period (Week 28-Week 76).
Participants will be randomized to APG777 + APG990 or dupilumab in a 1:1 ratio. Randomization will be stratified on Day 1 according to Baseline disease severity and geographic region.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Note: Additional protocol defined Inclusion/Exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive protocol specified combination dose of APG777 + APG990
Drug: APG777 · Drug: APG990
Participants will receive protocol specified dose of Dupilumab
Drug: Dupilumab
Number of Participants with Treatment Emergent Adverse Events (TEAEs)
Time frame: Up to 24 weeks
Predose Serum Concentrations (Ctrough) of APG777
PK parameters will be performed using a non-compartmental approach with a validated PK software.
Time frame: Baseline, Week 1, 2, 4, 8, 12, 16, 20, 24
Predose Serum Concentrations (Ctrough) of APG990
PK parameters will be performed using a non-compartmental approach with a validated PK software.
Time frame: Baseline, Week 1, 2, 4, 8, 12, 16, 20, 24
Maximum Serum Concentrations (Cmax) of APG777
PK parameters will be performed using a non-compartmental approach with a validated PK software
Time frame: Baseline, Week 1, 2, 4, 8, 12, 16, 20, 24
Maximum Serum Concentrations (Cmax) of APG990
PK parameters will be performed using a non-compartmental approach with a validated PK software.
Time frame: Baseline, Week 1, 2, 4, 8, 12, 16, 20, 24
Time to Reach Cmax (tmax) of APG777
PK parameters will be performed using a non-compartmental approach with a validated PK software. If the maximum value occurs at more than one time point, tmax is defined as the first time point with this value.
Time frame: Baseline, Week 1, 2, 4, 8, 12, 16, 20, 24
Time to Reach Cmax (tmax) of APG990
PK parameters will be performed using a non-compartmental approach with a validated PK software. If the maximum value occurs at more than one time point, tmax is defined as the first time point with this value.
Time frame: Baseline, Week 1, 2, 4, 8, 12, 16, 20, 24
Plan to share: No
Ran from Jun 2025 to primary completion in Aug 2026, 14 months.
Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 14 months is above that.
Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zumilokibart